Company intelligence / Profile preview
Liveyon
- Ownership
- Private
- Employees
- ~25
- Development stage
- Other
Overview
Liveyon manufactures and distributes umbilical cord blood–derived injectable stem cell products (PURE, PURE PRO, earlier ReGen/Premier MAXCB) that have been marketed for diverse orthopedic and systemic indications without FDA-approved biologics licenses or INDs; products have been subject to recalls, FDA warning letters, and DOJ criminal enforcement related to safety issues (including bacterial contamination) and false or misleading marketing claims.[1][2][6][9]
- Therapeutic areas
- ImmunologyOtherCardiovascularNeurologyPulmonologyRheumatologyPsychiatry
- Modalities
- Cell therapyStem cell therapyBiologic
- Industry
- Biotech
Drug pipeline
1 assetBeyond the preview
Go deeper on Liveyon.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Liveyon.